Last reviewed · How we verify
Zoledronic Acid Injection
At a glance
| Generic name | Zoledronic Acid Injection |
|---|---|
| Also known as | Taro-Zoledronic Acid, Dr. Reddy's Zoledronic Acid Injection, Yigu |
| Sponsor | University of Calgary |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea (PHASE3)
- Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults (PHASE2)
- Romosozumab Use to Build Skeletal Integrity (PHASE4)
- FARE Augmentation of Proximal Femoral Fractures With CaS/HA and Systemic ZA (PHASE4)
- Muscle Impact of Treating Osteoporosis (PHASE4)
- Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa (PHASE3)
- Step-down Therapy After Long-term Osteoporosis Treatment (PHASE4)
- Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention Following an Acute Knee Injury (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zoledronic Acid Injection CI brief — competitive landscape report
- Zoledronic Acid Injection updates RSS · CI watch RSS
- University of Calgary portfolio CI